Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD of BIOXYTRAN, INC from Q4 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Bioxytran, Inc quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and change rate from Q4 2010 to Q3 2025.
  • Bioxytran, Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 30 Sep 2025 was -$2.9M, a 168% decline year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

BIOXYTRAN, INC Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 -$2.9M -$1.82M -168% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$2.64M -$1.54M -140% 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$2.71M -$1.72M -173% 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$1.79M +$1.31M +42.3% 31 Dec 2024 10-Q 14 Nov 2025
Q3 2024 -$1.08M +$1.06M +49.4% 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$1.1M +$1.56M +58.7% 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$990K +$3.07M +75.6% 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$3.1M +$192K +5.83% 31 Dec 2023 10-Q 14 Nov 2025
Q3 2023 -$2.14M +$405K +15.9% 30 Sep 2023 10-Q 29 Oct 2024
Q2 2023 -$2.66M +$2.1M +44.1% 30 Jun 2023 10-Q 29 Oct 2024
Q1 2023 -$4.06M +$18.8K +0.46% 31 Mar 2023 10-Q 29 Oct 2024
Q4 2022 -$3.3M -$139K -4.39% 31 Dec 2022 10-K 03 Apr 2025
Q3 2022 -$2.55M -$632K -33% 30 Sep 2022 10-Q 03 Nov 2023
Q2 2022 -$4.76M -$3.45M -264% 30 Jun 2022 10-Q 03 Nov 2023
Q1 2022 -$4.08M -$1.59M -63.6% 31 Mar 2022 10-Q 03 Nov 2023
Q4 2021 -$3.16M -$1.22M -62.7% 31 Dec 2021 10-K/A 13 Jan 2025
Q3 2021 -$1.92M 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$1.31M 30 Jun 2021 10-Q 10 Nov 2022
Q1 2021 -$2.49M 31 Mar 2021 10-Q 10 Nov 2022
Q4 2020 -$1.94M -$1.14M -143% 31 Dec 2020 10-K 31 Mar 2023
Q4 2019 -$799K -$574K -255% 31 Dec 2019 10-K 18 Mar 2020
Q3 2019 -$1.18M -$1.13M -2272% 30 Sep 2019 10-Q 13 Nov 2019
Q2 2019 -$657K -$655K 30 Jun 2019 10-Q 13 Nov 2019
Q1 2019 -$655K -$654K 31 Mar 2019 10-Q 13 Nov 2019
Q4 2018 -$225K -$224K 31 Dec 2018 10-K 18 Mar 2020
Q3 2018 -$49.8K 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$1.98K* 30 Jun 2018 10-Q 13 Nov 2019
Q1 2018 -$1.31K* 31 Mar 2018 10-Q 13 Nov 2019
Q4 2017 -$1.31K* 31 Dec 2017 10-K 18 Mar 2020
Q3 2012 $125K -$44K -26% 30 Sep 2012 10-Q 21 Nov 2012
Q2 2012 $199K +$16.5K +9.08% 30 Jun 2012 10-Q/A 22 Jan 2013
Q1 2012 $156K 31 Mar 2012 10-Q/A 22 Jan 2013
Q4 2011 $163K +$219K 31 Dec 2011 10-Q/A 22 Jan 2013
Q3 2011 $169K 30 Sep 2011 10-Q/A 31 Dec 2012
Q2 2011 $182K 30 Jun 2011 10-Q/A 31 Dec 2012
Q4 2010 -$56K 31 Dec 2010 10-K/A 31 Dec 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.